palmidrol has been researched along with Colitis, Mucous in 2 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capasso, R | 1 |
| Orlando, P | 1 |
| Pagano, E | 1 |
| Aveta, T | 1 |
| Buono, L | 1 |
| Borrelli, F | 1 |
| Di Marzo, V | 2 |
| Izzo, AA | 1 |
| Cremon, C | 1 |
| Stanghellini, V | 1 |
| Barbaro, MR | 1 |
| Cogliandro, RF | 1 |
| Bellacosa, L | 1 |
| Santos, J | 1 |
| Vicario, M | 1 |
| Pigrau, M | 1 |
| Alonso Cotoner, C | 1 |
| Lobo, B | 1 |
| Azpiroz, F | 1 |
| Bruley des Varannes, S | 1 |
| Neunlist, M | 1 |
| DeFilippis, D | 1 |
| Iuvone, T | 1 |
| Petrosino, S | 1 |
| Barbara, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of the Oral Administration in IBS Patients of the Association of 200 mg Micronised Palmitoylethanolamide (PEA) and 20 mg Polydatin, on Parameters of Intestinal Inflammation and Visceral Hyperalgesia.[NCT01370720] | Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for palmidrol and Colitis, Mucous
| Article | Year |
|---|---|
Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Amides; Analgesics; Cell Count; Dietary Supplements; Double-Blind Method; Eth | 2017 |
1 other study available for palmidrol and Colitis, Mucous
| Article | Year |
|---|---|
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.
Topics: Amides; Animals; Colitis; Disease Models, Animal; Ethanolamines; Gastrointestinal Motility; Inflamma | 2014 |